Egypt Liver Cancer Therapeutics Market May Register an Impressive Growth Through 2027
The
rising geriatric population and the adoption of unhealthy lifestyles has
increased the risks of liver cancer, which is expected to drive the growth of
the Egypt Liver Cancer Therapeutics market in the upcoming five years.
According
to TechSci report on, “Egypt Liver Cancer
Therapeutics Market - By Region, Competition Forecast &
Opportunities, 2027”, the Egypt Liver Cancer Therapeutics market
may flourish with an impressive CAGR during the forecast period of 2023-2027,
on the backbone of the rising burden of liver cancer in Egypt. The rising risk
of liver cancer can be attributed to unhealthy lifestyle choices such as
smoking, high alcohol consumption, junk eating, sedentary lifestyle leading to
excess body weight, and other metabolic disorders. According to a credible
source, 27,895 new cases of liver cancer were recorded in Egypt, in 2020. As a
result, the demand for liver cancer therapeutic drugs is rising at a rapid
rate. Apart from this, the increasing research and development activities in
the development of new therapeutics for liver cancer are also providing
lucrative growth opportunities to the market. For instance, targeted therapies
are increasingly being preferred by healthcare professionals as they target the
proteins that control how cancer cell grows, spread, and divide. As researchers
are learning more about the DNA changes and proteins that lead to cancer, they
are able to get better insights and deliver treatments that target these
proteins. Moreover, the rising support from the governments in terms of
investment in the healthcare sector to make healthcare services affordable and
easily accessible is expected to propel the market for liver cancer
therapeutics in Egypt.
Browse over XX market data Figures spread through 70
Pages and an in-depth TOC on "EGYPT LIVER CANCER THERAPEUTICS MARKET"
The Egypt Liver Cancer Therapeutics market is
segmented by type, therapy, end user, competitional landscape, and regional
distribution. Based on type, the market is further segmented into
hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and others. Among
these, hepatocellular carcinomas (HCC) are expected to be the fastest growing
segment over the forecast period. This is primarily because HCC is the most
common form of liver cancer, which usually occurs in people suffering from
chronic liver diseases like cirrhosis. Globally also, HCC is one of the major
causes of cancer-related deaths. Moreover, several research studies confirmed
that people suffering from hepatocellular carcinoma are at a much higher risk
of contracting the infection. As a result, hepatocellular carcinoma is expected
to lead the segment and propel the Egypt liver cancer market over the coming
years.
By therapy, the market is bifurcated into targeted
therapy, radiation therapy, immunotherapy, chemotherapy, and others. The
chemotherapy segment has held a significant share over the past years, and it
is projected to remain dominant over the coming years. This is because
chemotherapy uses drugs to kill rapidly growing cancer cells. This therapy is
administered through veins in the patient’s arm or is given in pill form, or
both.
By end user, the market is divided between hospitals
& clinics, ambulatory care, and others. Among these, the hospitals &
clinics segment is expected to hold the largest market share over the coming
years. This is primarily because hospitals usually have fully developed
infrastructure with technologically advanced medical devices and equipment
required to perform the stent surgery. Moreover, hospitals and clinics offer
better after-surgery care due to the presence of highly skilled professionals
and nursing staff. In line with this, the rising focus on upgrading the
healthcare infrastructure is expected to fuel this segment of the Egypt Liver
Cancer Therapeutics market.
A list of major
market players of the Egypt Liver Cancer Therapeutics market includes:
- Roche Egypt LLC
- Bayer Middle East FZE
- Eli Lilly and Company (Egypt)
- Merck Egypt
- Novartis Egypt
DOWNLOAD FREE SAMPLE REPORT
Customers can also
request for 10% free customization on this report.
“Rapid
advancements in liver cancer therapies are strengthening the market growth. For
instance, FDA has recently approved an immunotherapy drug called Atezolizumab
Plus Bevacizumab. This drug is used with bevacizumab to treat some patients
with advanced liver cancer. Moreover, the Egypt government is continuously
taking initiatives to limit liver cancer and allow early detection, to improve
the chances of survival in patients. In addition, technological advances in
diagnosis and therapeutics to facilitate a higher acceptance rate of liver
transplant is also fueling the market growth. The new market players are
advised to enter the market with innovative and advanced therapies and
therapeutics available at an affordable cost to establish their name in the market.
They may also partner with international leaders to expand their customer
base,” said Mr. Karan Chechi, Research Director with TechSci Research, a
research based global management consulting firm.
“Egypt Liver Cancer
Therapeutics Market By Type (Hepatocellular Carcinoma,
Cholangiocarcinoma, Hepatoblastoma, Others), By Therapy (Targeted Therapy,
Radiation Therapy, Immunotherapy, Chemotherapy, Others), By End User (Hospitals
& Clinics, Ambulatory Care Centers, Others) By Region,
Competition Forecast & Opportunities, 2027” has evaluated the future growth potential of Egypt
Liver Cancer Therapeutics market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Egypt Liver
Cancer Therapeutics market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com